Published: Jul 28, 2021
HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2).
The collaboration brings together MD Anderson translational research scientists, the drug development capabilities of MD Anderson s Therapeutics Discovery division and Blueprint Medicines precision therapy pipeline and expertise. The teams seek to characterize the range of cancer types susceptible to treatment with a selective CDK2 inhibitor, advance BLU-222 mono- and combination-therapy strategies with the potential to maximize patient benefit, and identify novel biomarkers that may better predict treatment response and optimize patient selection.
T-Cypher Bio Announces Formation of Scientific Advisory Board
padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines Reports Second Quarter 2021 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Bristol Myers Seeks Redeeming Combination for Struggling Checkpoint Inhibitor
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.